Subscribe to Search results

It was the view of the reference centre directors at the special meeting on 13 May 1983 that cryoprecipitate was not particularly easy to use as there was no guarantee of the amount of Factor 8 in each bag, and it was not a particularly useful therapeutic option for major surgery or major bleeds.

Published on:

Inquiry publishes timetable for further evidence from panels and expert groups

Published on:

The results of a survey between Sheffield and the Royal Free on chronic hepatitis showed that approximately one third of the patients studied had the appearance of chronic active (aggressive) hepatitis.

Published on:

A letter to The Lancet in 1982 reported that "we have previously shown that there is a high incidence of chronic liver disease among patients receiving blood product concentrates even in the absence of any symptoms."

Published on:

The annual return for 1976 showed the Sheffield Haemophilia Centre treating its patients with cryoprecipitate, NHS Factor 8 and commercial concentrates.

Published on:

It was noted in the Annual Returns for Sheffield Haemophilia Centre for 1977 'that "home treatment packs' from ARMOUR have been used most of the time for home therapy."

Published on:

In 1979 the Sheffield Haemophilia Centre's return recorded no cryoprecipitate use at all for people with Haemophilia A.

Published on:

Annual returns for Sheffield Haemophilia Centre in 1980 recorded that a small amount of cryoprecipitate was used, but the mainstay of treatment was commercial concentrate

Published on:

In 1980, in the Sheffield Haemophilia Centre, a small amount of cryoprecipitate was used, but the majority of treatment was commercial concentrate (4,690 units of cryoprecipitate; 141,775 units of NHS concentrate; 800,852 units of commercial concentrates (Factorate, Hemofil, Kryobulin)).

Published on:

Professor Eric Preston stated in his statement that cryoprecipitate was not a treatment option for severe haemophiliacs, and that this did not change over time.

Published on:

In Birmingham, Haemophilia care was split between the Children's Hospital and the Queen Elizabeth Hospital. They were jointly designated as a haemophilia centre in the 1970s

Published on:

In 1976 Dr Frank Hill succeeded Dr Jillian Mann as director at the Children's Hospital; Dr John Stuart was director at QEH until 1983 when he was succeeded by Dr Ian Franklin

Published on:

The West Midlands Regional Health Authority Working Party on the Treatment of Haemophiliacs met regularly throughout the 1970s to discuss issues relating to supply

Published on:

In December 1975, the West Midlands Regional Health Authority recorded difficulties in producing sufficient plasma and it was agreed that commercial Factor 8 (Kryobulin) would need to be purchased at an annual cost to the region of £350,000.

Published on:

Demand for cryoprecipitate was going down and NHS concentrates were not being used at the rate that had been predicted

Published on:

In 1976 the Queen Elizabeth Hospital had used 500,000 units of commercial Factor 8 for home treatment, because all the NHS product having been used for treatment in hospital and for dental cases.

Published on:

During 1977 the Queen Elizabeth Hospital used significant amounts of commercial Factor 8 (almost double the amount from the previous year) as well as NHS Factor 8 (at a similar level to the previous year)

Published on:

At a Working Party meeting Dr Stuart stated that during 1976 Queen Elizabeth Hospital had used 500,000 units of commercial Factor 8 for home treatment, with all the NHS product having been used for treatment in hospital and for dental cases. He stated that his preference was to have all his Factor 8 from the same source, and that he was minded to discontinue cryoprecipitate as a home treatment and use NHS product instead.

Published on:

During 1977 Queen Elizabeth Hospital used significant amounts of commercial Factor 8 as well as NHS Factor 8

Published on:

Dr Stuart of Queen Elizabeth Hospital stated that only a third of Queen Elizabeth Hospital's Factor 8 product was received from the Lister, meaning the two-thirds shortfall had to be made up with commercial concentrates.

Published on: